Vamorolone (Agamree) Approved in Scotland

January 13, 2025

The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland.

The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.

SourceMuscular Dystrophy UK

Tags
AGAMREE
Scotland
Vamorolone

Nutrition Guideline for Duchenne Muscular Dystrophy: Foods to Eat and Avoid

Edgewise Therapeutics Announces Plans for 2025

Vamorolone (Agamree) Approved in Scotland

Cumberland Pharmaceuticals Announces Fantastic Results from Phase 2 FIGHT Duchenne Trial in DMD Heart Disease

Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201

Brazilian Children Over 7 and Their Families Demand Elevidys Gene Therapy from Anvisa

Ask the DMD Associations in Your Country: When Will Duchenne Treatments Come to Our Country?

DMD Warrior Mark Penzes from Hungary and His Family’s Determination to Receive Treatment

The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland.

LEAVE A REPLY Cancel reply

Hot Topics

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Cures of Duchenne (List of All Researches)

Capricor Therapeutics Submits Application for Treatment of DMD Cardiomyopathy

Related Articles

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera

About us

Latest Articles